PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Language and understanding: The complexity of insight in cancer care

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407